HOME >> BIOLOGY >> NEWS
Latest data shows MabThera provides significant, sustained relief from symptoms of RA

Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis (RA) is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission1. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.

Commenting on the findings, Professor Keystone, Rheumatology Department at the University of Toronto, Canada, said: "As physicians gain experience with MabThera and the long-term efficacy and safety data are collected, we are able to make treatment decisions with confidence for the ultimate benefit of our patients."

Results following subsequent courses of therapy

A total of 1053 RA patients was treated with MabThera with almost 70% of patients followed up for more than two years and 11% for more than three years. The study was conducted in patients who had an inadequate response to treatment with either tumour necrosis factor (TNF) inhibitors or disease-modifying anti-rheumatic drugs (DMARDs), both of which are commonly used classes of RA drugs. All study patients received multiple courses of MabThera (2 x1000mg infusion, 2 weeks apart) based on disease activity.

The data showed that after three courses of MabThera in patients who had an inadequate response to TNF inhibitors:

  • The number of patients achieving the hard-to-reach goal of a 70% improvement in disease signs and symptoms (ACR70 response2) almost tripled from 11% to 25%

  • The number of patients achieving remission improved from 6% to 12%

Equally, in patients with an inadequate response or intolerance to DMARDs, the remission rate increased almost threefold from 5% to 14% confirming the benefit of providing subsequen
'"/>

Contact: Lynn Huynh
lynn_huynh@uk.cohnwolfe.com
44-207-331-5332
Cohn & Wolfe, London
13-Jun-2007


Page: 1 2

Related biology news :

1. Latest strategies for moving research toward a cure for diabetes explored at global scientific forum
2. Latest plant health research to be presented in San Diego
3. Latest advances in DNA sequencing highlighted at DOE Joint Genome Institute User Meeting
4. Latest buzz: Marijuana may slow progression of Alzheimers disease
5. Latest enhancements to the free Access Grid Toolkit are now available for download
6. Slow-frozen people? Latest research supports possibility of cryopreservation
7. Latest plant disease research to be presented in Quebec City
8. Latest study: Scientists say no evidence exists that therapod dinosaurs evolved into birds
9. Latest gene therapy research to be presented in St. Louis, June 1-5, 2005
10. Latest census finds more American pika populations disappear as climate warms
11. Latest buzz in research: Intoxicated honey bees may clue scientists into drunken human behavior

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced ... will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional ... Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, ...
(Date:7/1/2020)... , ... July 01, 2020 , ... ... it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located ... existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted ... will cover the history of eSource, the reasons it did not take off as ... to site source, the industry is moving towards capturing data electronically for clinical trials ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter ... great surgery is only the beginning of a successful study, while protecting and accessing ... Brad Gien, Global Head of Surgery from Envigo in a live ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... products, announces a significant expansion of laboratory operations through its COVID-19 testing ... implementing testing programs. , Bode-CARES provides a turnkey solution that ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem ... 200 million stem cells. Depending on the patient's condition, treatment may be offered IV, ... die having some form of Alzheimers dementia, and the incidence continues to increase as ...
Breaking Biology Technology:
Cached News: